Lungs

5A2-SC8 is an ionizable amino lipid in lipid nanoparticles (LNPs) that shows high delivery potential and low in vivo toxicity, enabling efficient delivery of small RNAs such as siRNA and miRNA into tumor cells. 5A2-SC8 LNPs can confer a unique delivery fate of RNA within the liver, thereby changing the therapeutic outcomes in cancer models.

306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies.

244cis, a piperazine-containing ionizable cationic lipid, has been used to generate lipid nanoparticles (LNPs). LNPs containing 244cis and coated with mRNA reporter gene were specifically accumulated in mouse lungs compared with LNPs containing SM-102. Induces a decrease in serum chemokine (C-C motif) ligand 2 (CCL2) levels.

9A1P9 is a multi-tail ionizable cationic phospholipid. 9A1P9 induces membrane destabilization. 9A1P9 can be used for mRNA delivery t.

113-N16B is an ionizable cationic lipid that can be used for the synthesis of lipid nanoparticles. 113-N16B delivers mRNA to pulmonary endothelial cells. 113-N16B can be formulated as a component into hybrid lipid nanoparticles for lung-specific delivery of mRNA (including MFSD7C mRNA and luciferase mRNA) in mice. 113-N16B is applicable to research related to lymphangioleiomyomatosis, sickle cell disease, and hemolysis-induced lung injury.

RCB-02-4-8 is an ionizable cationic lipid that is used to form lipid nanoparticles (LNPs) to deliver mRNA. RCB-02-4-8 can improve the efficiency of lung transfection in mice.

DSG-PEG2000-GALA (DSG-PEG2000-Mal-Cys-WEAALAEALAEALAEHLAEALAEALEALAA) is a functionalized PEGylated phospholipid conjugate composed of three modular components: distearoylglycerol (DSG) as a lipid anchoring group, a 2000 Da polyethylene glycol (PEG) spacer arm, and a GALA (HY-P5423) peptide as a terminal targeting/functional ligand. DSG-PEG2000-GALA can be used for pH-responsive drug delivery, endosome escape and cytoplasmic drug release, and cytoplasmic delivery of nucleic acids (siRNA/mRNA).

DSG-PEG2000-VIP (DSG-PEG2000-Mal-Cys-HSDAVFTDNYTRLRKQMAVKKYLNSILN) is a functionalized PEGylated phospholipid conjugate composed of three modular components: distearoylglycerol (DSG) as a lipid anchoring group, a 2000 Da polyethylene glycol (PEG) spacer arm, and a VIP peptide as a terminal targeting/functional ligand. DSG-PEG2000-VIP can be used in research such as targeted drug delivery for breast cancer.

DMG-PEG2000-VIP (DMG-PEG2000-Mal-Cys-HSDAVFTDNYTRLRKQMAVKKYLNSILN) is a functionalized PEGylated phospholipid conjugate composed of three modular components: 1,2-dipalmitoyl-sn-glycerol-3-phosphoethanolamine (DMG) as a lipid anchoring group, a 2000 Da polyethylene glycol (PEG) spacer arm, and a VIP peptide as a terminal targeting/functional ligand. DMG-PEG2000-VIP can be used in research such as targeted drug delivery for breast cancer.

DMG-PEG2000-GALA (DMG-PEG2000-Mal-Cys-WEAALAEALAEALAEHLAEALAEALEALAA) is a functionalized PEGylated phospholipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as a lipid anchoring group, a 2000 Da polyethylene glycol (PEG) spacer arm, and a GALA (HY-P5423) peptide as a terminal targeting/functional ligand. DMG-PEG2000-GALA can be used for pH-responsive drug delivery, endosome escape and cytoplasmic drug release, and cytoplasmic delivery of nucleic acids (siRNA/mRNA).

DSPE-PEG5000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG5000-GALA can be used for drug delivery.

DSPE-PEG1000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG1000-GALA can be used for drug delivery.

DSPE-PEG3400-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG3400-GALA can be used for drug delivery.

DSPE-PEG2000-GALA is a PEG compound which composed of DSPE and a lung endothelium-targeting peptide GALA (HY-P5423). GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. DSPE-PEG2000-GALA can be used for drug delivery.

DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery.

DSPE-PEG3400-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG3400-VIP can be used for drug delivery.

DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery.

DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery.

9C-SCC-10 is a crown-like biodegradable ionizable lipid. 9C-SCC-10 an be used to prepare lipid nanoparticles for delivering mRNA and targeting lung tissue. 9C-SCC-10 can be used for early detection and diagnosis of lung cancer.

514O6,10 is an ionizable lipidoid containing a branched-tail. 514O6,10 can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to natural killer and dendritic cells within the lung. 514O6,10 can be used for the RNA therapies for lung diseases associated with immune cell dysregulation, including cancer, viral infections, and autoimmune disorders research.